vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Array Technologies, Inc.（ARRY）财务数据对比。点击上方公司名可切换其他公司
Array Technologies, Inc.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.2倍（$226.0M vs $183.1M），Amphastar Pharmaceuticals, Inc.同比增速更快（-1.8% vs -17.9%），Array Technologies, Inc.自由现金流更多（$36.2M vs $24.6M），过去两年Array Technologies, Inc.的营收复合增速更高（21.4% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
ATI科技是原加拿大半导体科技企业，总部位于安大略省万锦市，专注于图形处理器与芯片组的研发，1985年成立，1993年公开上市，2006年被AMD收购。作为全球知名的无晶圆厂半导体厂商，其掌握自研核心技术，生产组装环节采用外包模式。2000年3dfx破产后，ATI成为全球图形芯片领域的核心厂商之一。
AMPH vs ARRY — 直观对比
营收规模更大
ARRY
是对方的1.2倍
$183.1M
营收增速更快
AMPH
高出16.0%
-17.9%
自由现金流更多
ARRY
多$11.6M
$24.6M
两年增速更快
ARRY
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $226.0M |
| 净利润 | $24.4M | — |
| 毛利率 | 46.8% | 8.6% |
| 营业利润率 | 19.4% | -65.5% |
| 净利率 | 13.3% | — |
| 营收同比 | -1.8% | -17.9% |
| 净利润同比 | -35.7% | — |
| 每股收益（稀释后） | $0.51 | $-1.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHARRY
| Q4 25 | $183.1M | $226.0M | ||
| Q3 25 | $191.8M | $393.5M | ||
| Q2 25 | $174.4M | $362.2M | ||
| Q1 25 | $170.5M | $302.4M | ||
| Q4 24 | $186.5M | $275.2M | ||
| Q3 24 | $191.2M | $231.4M | ||
| Q2 24 | $182.4M | $255.8M | ||
| Q1 24 | $171.8M | $153.4M |
净利润AMPHARRY
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $33.5M | ||
| Q2 25 | $31.0M | $43.3M | ||
| Q1 25 | $25.3M | $16.7M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $-141.4M | ||
| Q2 24 | $37.9M | $25.7M | ||
| Q1 24 | $43.2M | $2.2M |
毛利率AMPHARRY
| Q4 25 | 46.8% | 8.6% | ||
| Q3 25 | 51.4% | 26.9% | ||
| Q2 25 | 49.6% | 26.8% | ||
| Q1 25 | 50.0% | 25.3% | ||
| Q4 24 | 46.5% | 28.5% | ||
| Q3 24 | 53.3% | 33.8% | ||
| Q2 24 | 52.2% | 33.6% | ||
| Q1 24 | 52.4% | 35.9% |
营业利润率AMPHARRY
| Q4 25 | 19.4% | -65.5% | ||
| Q3 25 | 13.2% | 11.6% | ||
| Q2 25 | 24.2% | 12.8% | ||
| Q1 25 | 21.9% | 9.0% | ||
| Q4 24 | 24.2% | -51.7% | ||
| Q3 24 | 29.8% | -57.3% | ||
| Q2 24 | 30.3% | 15.5% | ||
| Q1 24 | 27.9% | 5.5% |
净利率AMPHARRY
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 8.5% | ||
| Q2 25 | 17.8% | 11.9% | ||
| Q1 25 | 14.8% | 5.5% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | -61.1% | ||
| Q2 24 | 20.8% | 10.0% | ||
| Q1 24 | 25.1% | 1.4% |
每股收益（稀释后）AMPHARRY
| Q4 25 | $0.51 | $-1.06 | ||
| Q3 25 | $0.37 | $0.12 | ||
| Q2 25 | $0.64 | $0.19 | ||
| Q1 25 | $0.51 | $0.02 | ||
| Q4 24 | $0.74 | $-0.94 | ||
| Q3 24 | $0.78 | $-1.02 | ||
| Q2 24 | $0.73 | $0.08 | ||
| Q1 24 | $0.81 | $-0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $244.4M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $-206.3M |
| 总资产 | $1.6B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHARRY
| Q4 25 | $282.8M | $244.4M | ||
| Q3 25 | $276.2M | $221.5M | ||
| Q2 25 | $231.8M | $377.3M | ||
| Q1 25 | $236.9M | $348.3M | ||
| Q4 24 | $221.6M | $363.0M | ||
| Q3 24 | $250.5M | $332.4M | ||
| Q2 24 | $217.8M | $282.3M | ||
| Q1 24 | $289.6M | $287.6M |
总债务AMPHARRY
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHARRY
| Q4 25 | $788.8M | $-206.3M | ||
| Q3 25 | $776.7M | $-46.7M | ||
| Q2 25 | $757.5M | $-70.9M | ||
| Q1 25 | $751.3M | $-97.8M | ||
| Q4 24 | $732.3M | $-118.1M | ||
| Q3 24 | $727.7M | $64.5M | ||
| Q2 24 | $713.3M | $200.0M | ||
| Q1 24 | $672.4M | $231.2M |
总资产AMPHARRY
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.7B | $1.6B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.4B | ||
| Q4 24 | $1.6B | $1.4B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.5B | $1.7B | ||
| Q1 24 | $1.6B | $1.6B |
负债/权益比AMPHARRY
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $43.6M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $36.2M |
| 自由现金流率自由现金流/营收 | 13.4% | 16.0% |
| 资本支出强度资本支出/营收 | 4.5% | 3.3% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $79.8M |
8季度趋势，按日历期对齐
经营现金流AMPHARRY
| Q4 25 | $32.9M | $43.6M | ||
| Q3 25 | $52.6M | $27.4M | ||
| Q2 25 | $35.6M | $43.8M | ||
| Q1 25 | $35.1M | $-13.1M | ||
| Q4 24 | $29.0M | $57.6M | ||
| Q3 24 | $60.0M | $44.9M | ||
| Q2 24 | $69.1M | $4.0M | ||
| Q1 24 | $55.3M | $47.5M |
自由现金流AMPHARRY
| Q4 25 | $24.6M | $36.2M | ||
| Q3 25 | $47.2M | $21.9M | ||
| Q2 25 | $25.0M | $37.2M | ||
| Q1 25 | $24.4M | $-15.4M | ||
| Q4 24 | $16.6M | $55.9M | ||
| Q3 24 | $46.2M | $43.9M | ||
| Q2 24 | $63.1M | $1.8M | ||
| Q1 24 | $46.5M | $45.1M |
自由现金流率AMPHARRY
| Q4 25 | 13.4% | 16.0% | ||
| Q3 25 | 24.6% | 5.6% | ||
| Q2 25 | 14.3% | 10.3% | ||
| Q1 25 | 14.3% | -5.1% | ||
| Q4 24 | 8.9% | 20.3% | ||
| Q3 24 | 24.1% | 19.0% | ||
| Q2 24 | 34.6% | 0.7% | ||
| Q1 24 | 27.1% | 29.4% |
资本支出强度AMPHARRY
| Q4 25 | 4.5% | 3.3% | ||
| Q3 25 | 2.8% | 1.4% | ||
| Q2 25 | 6.1% | 1.8% | ||
| Q1 25 | 6.3% | 0.8% | ||
| Q4 24 | 6.7% | 0.6% | ||
| Q3 24 | 7.2% | 0.5% | ||
| Q2 24 | 3.3% | 0.8% | ||
| Q1 24 | 5.1% | 1.6% |
现金转化率AMPHARRY
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 0.82× | ||
| Q2 25 | 1.15× | 1.01× | ||
| Q1 25 | 1.39× | -0.78× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | 0.15× | ||
| Q1 24 | 1.28× | 21.94× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
ARRY
| Array Legacy Operations Segment | $212.0M | 94% |
| STI Operations Segment | $14.0M | 6% |
